MedTrace Logo

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

NCT00769795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-03-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether combination treatment of prostate cancer with IMC-A12 (an antibody which blocks insulin-like growth factor receptor activity) with hormonal therapy (testosterone lowering) before prostatectomy, will be more effective than prior results with hormonal therapy alone.

Conditions

Interventions

DRUG

IMC-A12

IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.

DRUG

Bicalutamide

Bicalutamide 50 mg daily orally for 12 weeks

DRUG

Goserelin

10.8 mg subcutaneous once

Sponsors & Collaborators

Principal Investigators

  • Bruce Montgomery, M.D. · University of Washington and Seattle Cancer Care Alliance

  • James P Dean, M.D., Ph.D. · University of Washington and Seattle Cancer Care Alliance

  • Stephen Plymate, M.D. · University of Washington

  • John M Corman, MD · Virginia Mason Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-08-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769795 on ClinicalTrials.gov